Advertisement

Changes of CD4+ CD25+ regulatory T cells in peripheral blood in patients with hepatocellular carcinoma before and after TACE

  • Bin Xiong (熊 斌)
  • Gansheng Feng (冯敢生)
  • Shihua Luo (罗仕华)
  • Huimin Liang (梁惠民)
  • Lingyun Qiu (邱凌云)
  • Chuansheng Zheng (郑传胜)
  • Xi Liu (柳 曦)
  • Guofeng Zhou (周国锋)
Article

Summary

This study investigated the changes of CD4+ CD25+ regulatory T cells (Tregs) in peripheral blood of patients with hepatocellular carcinoma before and after transcatheter arterial chemoembolization (TACE). The proportion of CD4+ CD25+ Tregs among CD4+ T lymphocytes in peripheral blood of 33 patients with hepatocellular carcinoma was determined by flow cytometry before, 1 week and 1 month after TACE. And 25 healthy volunteers served as control. One month after TACE, the patients were divided into two groups: 22 in group A, who were in stable condition or getting better; and 10 in group B, who were deteriorating. One patient died and was excluded. The results showed that the percentage of CD4+CD25+ Tregs among CD4+ T lymphocytes did not significantly change in the 33 patients 1 week after TACE as compared with that before TACE, however, the difference was significant (P<0.01) between the patients with hepatocellular carcinoma and the healthy subjects. The percentage of CD4+ CD25+ Tregs among CD4+ T lymphocytes in group A 1 month after TACE was decreased significantly in comparison with that before and 1 week after TACE (P<0.01), whereas, that in group B was increased significantly 1 month after TACE (P<0.01). It was concluded that patients with hepatocellular carcinoma had a higher proportion of CD4+CD25+ Tregs in peripheral blood. TACE did not significantly affect the level of CD4+ CD25+ Tregs within short time (such as 1 week). The proportion of CD4+CD25+ Tregs in peripheral blood 1 month after TACE was related to the prognosis of hepatocellular carcinoma.

Key words

hepatocellular carcinoma regulatory T cells transcatheter arterial chemoembolization 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cao M, Cabrera R, Xu Y et al. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4+ CD25+ regulatory T cells. Lab Invest, 2007,87(6): 582–590PubMedGoogle Scholar
  2. 2.
    Sakaguchi S, Sakaguchi N, Asano M et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol, 1995,155:1151–1164PubMedGoogle Scholar
  3. 3.
    Woo E Y, Yeh H, Chu C S et al. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol, 2002,168:4272–4276PubMedGoogle Scholar
  4. 4.
    Dercamp C, Chemin K, Caux C et al. Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses. Cancer Res, 2005,65:8479–8486PubMedCrossRefGoogle Scholar
  5. 5.
    Unitt E, Rushbrook S M, Marshall A et al. Compromised lymphocytes infiltrate hepatocellular carcinoma: The role of T-regulatory cells. Hepatology, 2005,41(4):722–730PubMedCrossRefGoogle Scholar
  6. 6.
    Ghiringhelli F, Menard C, Terme M et al. CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor beta-dependent manner. J Exp Med, 2005,202:1075–1085PubMedCrossRefGoogle Scholar
  7. 7.
    Ormandy L A, Hillemann T, Wedemeyer H et al. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res, 2005,65(6):2457–2464PubMedCrossRefGoogle Scholar
  8. 8.
    Itoh M, Takahashi T, Sakaguchi N et al. Thymus and autoimmunity: production of CD4+ CD25+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol, 1999,162(2):5317–5326PubMedGoogle Scholar
  9. 9.
    Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell, 2000,101:455–458PubMedCrossRefGoogle Scholar
  10. 10.
    Morse M A, Clay T M, Mosca P et al. Immunoregulatory T cells in cancer immunotherapy. Expert Opin Biol Ther, 2002,2:827–834PubMedCrossRefGoogle Scholar
  11. 11.
    Sojka K D, Huang Y H, Fowell D J. Mechanisms of regulatory T-cell suppression—a diverse arsenal for a moving target. Immunology, 2008,14 (Epub ahead of print)Google Scholar
  12. 12.
    Menard C, Martin F, Apetoh L et al. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol Immunother, 2008, 28 (Epub ahead of print)Google Scholar
  13. 13.
    Woo E Y, Yeh H, Chu C S et al. Cutting Edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol, 2002,168:4272–4276PubMedGoogle Scholar
  14. 14.
    Curiel T, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med, 2004,10: 942–949PubMedCrossRefGoogle Scholar
  15. 15.
    Miller A M, Lundberg K, Ozenci V et al. CD4+ CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J Immunol, 2006,177:7398–7405PubMedGoogle Scholar
  16. 16.
    Liyanage U K, Moore T T, Joo H G et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol, 2002,169:2756–2761PubMedGoogle Scholar
  17. 17.
    Hiraoka N, Onozato K, Kosuge T et al. Prevalence of FOXP3t regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res, 2006,12:5423–5434PubMedCrossRefGoogle Scholar
  18. 18.
    Peng Q Q, Li S P, Xu L et al. Clinical Significance of the proportion of CD4+ CD25+ regulatory T cells in peripheral blood of hepatocellular carcinoma patients: A report of 117 cases. Chin J Cancer (Chinese), 2007,26(7):748–751Google Scholar
  19. 19.
    Sasaki A, Tanaka F, Mimori K et al. Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular carcinoma. Eur J Surg Oncol, 2008,34(2):173–179PubMedGoogle Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag GmbH 2008

Authors and Affiliations

  • Bin Xiong (熊 斌)
    • 1
  • Gansheng Feng (冯敢生)
    • 1
  • Shihua Luo (罗仕华)
    • 1
  • Huimin Liang (梁惠民)
    • 1
  • Lingyun Qiu (邱凌云)
    • 1
  • Chuansheng Zheng (郑传胜)
    • 1
  • Xi Liu (柳 曦)
    • 1
  • Guofeng Zhou (周国锋)
    • 1
  1. 1.Department of Radiology, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina

Personalised recommendations